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In Brief
Both Sarm1 deletion and WldS prevent
axonopathy and perinatal lethality in
NMNAT2-deficient mice. Gilley et al.
report that those rescued by WldS
develop hindlimb motor problems as
young adults, whereas Sarm1 deletion
allows survival to 24 months with no overt
defect. These findings have important
analytical and therapeutic implications.
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Studies with the WldS mutant mouse have shown
that axon and synapse pathology in several models
of neurodegenerative diseases are mechanistically
related to injury-induced axon degeneration (Waller-
ian degeneration). Crucially, an absence of SARM1
delays Wallerian degeneration as robustly as WldS,
but their relative capacities to confer long-term pro-
tection against related, non-injury axonopathy and/
or synaptopathy have not been directly compared.
While Sarm1 deletion or WldS can rescue perinatal
lethality and widespread Wallerian-like axonopathy
in young NMNAT2-deficient mice, we report that an
absence of SARM1 enables these mice to survive
into old age with no overt phenotype, whereas those
rescued by WldS invariantly develop a progressive
neuromuscular defect in their hindlimbs from around
3 months of age. We therefore propose Sarm1 dele-
tion as amore reliable tool thanWldS for investigating
Wallerian-like mechanisms in disease models and
suggest that SARM1 blockade may have greater
therapeutic potential than WLDS-related strategies.INTRODUCTION
WldS, a spontaneous mutant mouse allele encoding a fusion
protein (WLDS) with nicotinamide mononucleotide adenylyl-
transferase (NMNAT) activity, robustly delays injury-induced
axon and synapse degeneration (Wallerian degeneration) by
locally substituting for loss of the endogenous NMNAT2 isoform
(Mack et al., 2001; Gilley and Coleman, 2010; Cohen et al., 2012;
Conforti et al., 2014).WldS has been the tool of choice for inves-
tigating the molecular basis of axon pathology in animal models
of neurodegenerative diseases and has revealed an involvement
of Wallerian-like mechanisms in several cases (Conforti et al.,
2014). Key steps in this process are thus potential targets for
intervention in patients.
Sterile alpha and TIR motif-containing protein 1 (SARM1) acts
downstream of NMNAT2 loss to promote axon degeneration
(Osterloh et al., 2012; Gerdts et al., 2013; Gilley et al., 2015; Lor-10 Cell Reports 21, 10–16, October 3, 2017 ª 2017 The Author(s).
This is an open access article under the CC BY license (http://creativeeto et al., 2015; Walker et al., 2017). Depletion of SARM1 is, to
date, the only othermanipulation that can delayWallerian degen-
eration and related axon degeneration in mice as robustly as
exogenous expression of WLDS or other NMNAT variants (Con-
forti et al., 2014), but its effectiveness in maintaining the long-
term health of axons and synapses in mouse models of axonop-
athy and/or synaptopathy has not yet been directly compared to
WldS. Such a comparison is needed to ascertain the relative
usefulness of Sarm1 deletion in determining whether Wallerian-
like mechanisms are involved in models of neurodegeneration
and should be informative in terms of therapeutic strategies for
those disorders.
An absence of NMNAT2 inmice causeswidespread axon trun-
cation during embryogenesis and perinatal lethality (Gilley et al.,
2013). Early rescue by WldS (dose dependently) or by Sarm1
deletion has shown that outgrowth of NMNAT2-deficient axons
stalls due to a Wallerian-like degenerative mechanism (Gilley
et al., 2013, 2015). Reduced NMNAT2 levels have already been
linked to tauopathy in mice and to decreased cognitive function
in humans (Ljungberg et al., 2012; Ali et al., 2016), but the severity
of the phenotype in mice lacking NMNAT2 suggests a complete
lack of the protein is unlikely to directly model any neurodegen-
erative conditions. Nevertheless, these mice represent a well-
defined and robust system for comparing the longer-term
protective effects of WldS and Sarm1 deletion against a severe
Wallerian-like axonopathy. While the survival of NMNAT2-defi-
cient mice homozygous for either WldS or a Sarm1 knockout
allele up to 3 months of age with no overt problems initially sug-
gested similarly robust rescue in each case (Gilley et al., 2013,
2015), we now report striking age-dependent differences be-
tween the two lines, which are likely to have important experi-
mental and therapeutic implications.RESULTS
LocomotorDefectsandMuscleAtrophy inNmnat2gtE/gtE;
WldS/S Mice, but Not Nmnat2gtE/gtE;Sarm1/ Mice
Mice homozygous for the Nmnat2gtE gene trap allele, lacking
NMNAT2, that are additionally homozygous for WldS or a
Sarm1 knockout allele (Nmnat2gtE/gtE;WldS/S or Nmnat2gtE/gtE;
Sarm1/ mice, respectively) are born at the expected fre-
quencies and are outwardly indistinguishable from NMNAT2-ex-
pressing littermates up to 3months of age (Table S1) (Gilley et al.,commons.org/licenses/by/4.0/).
Figure 1. Progressive Locomotor Dysfunc-
tion and Hindlimb Muscle Atrophy in
Nmnat2gtE/gtE;WldS/S Mice, but Not
Nmnat2gtE/gtE;Sarm1/ Mice
(A and B) Latency to fall in an accelerating Rotarod
task for mice of the indicated genotypes and ages.
Means ± SEM are plotted (maximum test duration,
300 s) for n = 7/8 male mice of each genotype (A)
(***p < 0.001 in two-way ANOVA with Dunnett’s
multiple comparisons) and n = 7 female mice of
each genotype (B) (NS, not significant [p = 0.29] in
t test).
(C) Representative transverse sections of
gastrocnemius muscle for mice of the selected
genotypes and ages (as indicated) stained with
H&E.Modest fiber atrophy is seen inNmnat2gtE/gtE;
WldS/S gastrocnemius at 10 weeks, and more
severe atrophy, with centrally located nuclei,
hypertrophic fibers (*), and pyknotic nuclear
clumps (arrow), is evident at 10 months. Images
are representative of male and female mice at
10 weeks and 8–12 months but just female mice at
24 months.
(D and E) Gastrocnemius muscle weights for mice
of the indicated genotypes and ages. Individual
animal values with means ± SEM are plotted for
n = 3–5 male mice per group (D) (*p < 0.05 and
***p < 0.001 in one-way ANOVA with Tukey’s mul-
tiple comparisons; NS, not significant) and n = 4–5
female mice per group (E) (*p < 0.05 in t test).
See also Movies S1, S2, S3, S4, S5, and S6, Table
S1, and Figure S1.2013, 2015). However, despite continued silencing of the trap-
ped Nmnat2 alleles in each case (Figure S1A), further aging
has revealed clear differences between the lines: Nmnat2gtE/gtE;
Sarm1/ mice remarkably survived for up to 2 years with
no noticeable behavioral deficiency or phenotype, whereas
Nmnat2gtE/gtE;WldS/Smice invariantly developed a conspicuous,
progressive hindlimb defect from around 3–5 months of age.
The defect inNmnat2gtE/gtE;WldS/Smice (male and female) first
presented as a modest hindlimb gait abnormality during sponta-Cneous locomotion, but this progressively
deteriorated, resulting in mice invariantly
dragging their hindlimbs regularly dur-
ing locomotion from around 6 months
onward as a result of worsening para-
paresis (Movies S1, S2, S3, and S4).
Consistent with this, locomotor ability of
Nmnat2gtE/gtE;WldS/S mice in an acceler-
ating Rotarod task deteriorated rapidly
between 4 and 6 months (Figure 1A).
Movement became so limited by 10–
12 months that it impaired free access to
food and water, so Nmnat2gtE/gtE;WldS/S
mice were not aged further. In contrast,
locomotor performance of Nmnat2gtE/gtE;
Sarm1/ mice did not decline during
the same period (Figure 1A; Movies S5
and S6), and Nmnat2gtE/gtE;Sarm1/mice still performed as well as Sarm1/ controls up to at least
15 months (Figure 1B).
Deteriorating locomotor function in Nmnat2gtE/gtE;WldS/Smice
coincided with progressive and widespread wasting of hindlimb
muscles (Figure S1B). A specific analysis of gastrocnemius mus-
cle revealed evidence of some muscle fiber atrophy and slightly
reduced muscle weight even at 10 weeks in Nmnat2gtE/gtE;
WldS/S mice, before the onset of overt locomotor dysfunction,
but this had progressed to severe muscle fiber atrophy andell Reports 21, 10–16, October 3, 2017 11
Figure 2. Progressive Loss of NMJ Inner-
vation in Gastrocnemius Muscles of
Nmnat2gtE/gtE;WldS/S Mice, but Not
Nmnat2gtE/gtE;Sarm1/ Mice
(A) Percentage of fully occupied (full), partially
occupied (partial), and denervated endplates in
gastrocnemius muscles from mice of the indicated
genotypes and ages. Endplate occupancy was
determined by assessing signal overlap between
a-bungarotoxin labeling of acetylcholine receptors
in the motor endplate and bIII-tubulin immuno-
staining of axon terminals (see Experimental Pro-
cedures). Total numbers of NMJs analyzed in
muscles from 3–5 mice per genotype (male and
female) are listed at the base of each column.
Means ± SEM of occupancy per animal are plotted
(NS, not significant [p > 0.05] or ***p < 0.001 in one-
way ANOVA with Tukey’s multiple comparisons of
full innervation, selected comparisons).
(B) Representative confocal z series projections of fixed gastrocnemius (Gn) muscle preparations showing merged a-bungarotoxin (red) and bIII-tubulin (green)
signals. Endplates in the images are marked as fully occupied (asterisks), partially occupied (arrows), or denervated (arrowheads).loss of mass by 10 months (Figures 1C and 1D). In contrast, no
muscle fiber atrophy or loss of mass was seen in Nmnat2gtE/gtE;
Sarm1/ gastrocnemius up to 24 months (Figures 1C–1E).
Although Nmnat2gtE/gtE;WldS/S mice did not lose body weight
between 10 weeks and 10–12 months, they failed to gain weight
as expected (Figure S1C). This presumably reflected loss of
muscle mass in the hindlimb being broadly matched by normal
weight gain in the upper torso and forelimbs, which appeared
largely unaffected. In contrast, developmental weight gain in
Nmnat2gtE/gtE;Sarm1/micewas comparable toSarm1/ con-
trols up to 24 months (Figure S1D).
Neuromuscular Denervation in Nmnat2gtE/gtE;WldS/S
Mice, but Not Nmnat2gtE/gtE;Sarm1/ Mice
Changes in neuromuscular junction (NMJ) innervation indicated
that the muscle defect in Nmnat2gtE/gtE;WldS/S mice is neuro-
genic. Motor endplate occupancy in Nmnat2gtE/gtE;WldS/S
gastrocnemius was found to be moderately reduced at
10 weeks, but consistent with the timing of gastrocnemius mus-
cle fiber atrophy and weight loss in these mice, by 10 months,
denervation was extensive, with only around 10% of endplates
showing normal innervation (Figures 2A and 2B).
We also investigated motor endplate occupancy in a more
distal hindlimb muscle, flexor digitorum brevis (FDB), at
10months. Although denervation was also evident in this muscle
(Figure 3A), it was less severe than in gastrocnemius at the same
age. Clear regional variation in the pattern of endplate occu-
pancy was seen in FDB, with discrete zones of normal innerva-
tion being found adjacent to zones of complete denervation (Fig-
ures 3B and 3C). Isometric tension recordings indicated that this
distinctive pattern of NMJ innervation reflects discrete loss of
entire motor units (Figures 3D and 3E), with apparently normal
function of remaining motor units (Figure S2).
In contrast, and consistent with the lack of locomotor prob-
lems, no significant endplate denervation and/or motor unit
loss was evident in either gastrocnemius or FDB muscles from
10-month-old Nmnat2gtE/gtE;Sarm1/ mice (Figures 2, 3A, 3D,
3E, and S2) and innervation remained comparable to Sarm1/12 Cell Reports 21, 10–16, October 3, 2017controls at 24 months, despite modest age-dependent denerva-
tion in both (Figure 2A).
WldS/S and Sarm1/ mice both performed maximally in
locomotor tests, and neither showed signs of neuromuscular
denervation at the ages studied. Although a direct comparison
with wild-type mice will be needed to establish whether more
subtle differences in motor function exist in either line, our
data suggest that both have broadly normal neuromuscular
function. The defect in Nmnat2gtE/gtE;WldS/S mice thus
appears to be specific to a declining inability of WLDS to counter
the lack of NMNAT2 in older mice, rather than other intrinsic
differences.
No Loss of Myelinated Tibial Nerve Axons in Either
Nmnat2gtE/gtE;WldS/S or Nmnat2gtE/gtE;Sarm1/ Mice
Despite progressive denervation of motor endplates in hindlimb
muscles from Nmnat2gtE/gtE;WldS/S mice, no concurrent loss of
myelinated axons was seen in the tibial nerve (Figure 4A) and
axons remained morphologically normal (Figure 4B). A gross
assessment revealed that most hindlimb muscles became
extensively atrophied in these mice (Figure S1B), so significantly
reduced numbers of axons would have been expected, even
in a mixed nerve such as this, if motor axon loss was the under-
lying cause. The age-dependent neuromuscular denervation in
Nmnat2gtE/gtE;WldS/Smuscles thus appears to result from selec-
tive loss of the distal ends of motor axons and/or their terminals.
This mirrors the age-dependent loss of protection of synapses
at NMJs after axotomy in homozygous WldS mice, despite
continued protection of the main body of the transected axon
(Gillingwater et al., 2002).
Counts of myelinated axons in Nmnat2gtE/gtE;Sarm1/ tibial
nerves remained comparable to those of Sarm1/ controls,
even up to 24 months (Figure 4A), with no age-related axon loss
in either group up to this age. We also found no significant axon
loss in a separate cohort of wild-type mice (on a related back-
ground) up to 24 months (1,514 ± 22 myelinated axons at
1.5months, compared to 1,473±40at 24months). This contrasts
a previous study that reported significant loss ofmyelinated tibial
Figure 3. Localized Loss of NMJ Innervation
from Distinct Motor Unit Groups in FDB
Muscle of Nmnat2gtE/gtE;WldS/S Mice
(A) Percentage of fully occupied (full), partially
occupied (partial), and denervated endplates in
FDB muscles of 10-month-old mice of the indi-
cated genotypes (method as in Figure 2A). Total
numbers of NMJs analyzed in muscles from 5–9
mice per genotype (male and female) are listed at
the base of each column. Means ± SEM of occu-
pancy per animal are plotted (NS, not significant
[p > 0.05] or **p < 0.01 in one-way ANOVA with
Tukey’s multiple comparisons of full innervation,
selected comparisons).
(B) Percentage of full occupancy of endplates per
imaged field revealed a zonal pattern of denerva-
tion in Nmnat2gtE/gtE;WldS/S FDB at 10 months,
with more widespread denervation in gastrocne-
mius (Gn). Fields with normal levels of full occu-
pancy (80%–100%) were relatively common in
FDB (7/18) but absent in gastrocnemius (average
of 16.9 and 11.6 endplates per field, respectively).
(C) Representative confocal z series projections of
fixed FDB muscle preparations showing merged
a-bungarotoxin (red) andbIII-tubulin (green) signals,
highlighting regional variability in Nmnat2gtE/gtE;
WldS/S endplate occupancy at 10 months. In addi-
tion to regions with widespread full occupancy (top
panel) or denervation (middle panel), there were
areas containing degenerated endplates (bottom
panel, not included in quantifications).
(D) Isometric twitch tension recordings for repre-
sentative Nmnat2gtE/gtE;WldS/S and Nmnat2gtE/gtE;
Sarm1/ FDB muscle-tibial nerve preparations
showing progressive, discrete recruitment of
motor units (incremental steps in twitch tension)
during continuously graded stimulation of the
nerve.
(E) Motor unit numbers in FDBmuscles from 10-month-old male mice of the indicated genotypes (n = 4 or 6 muscles from 2 or 3mice as shown). Individual values
and means ± SEM are plotted (NS, not significant [p > 0.99] or ***p < 0.001 in one-way ANOVA with Tukey’s multiple comparisons, selected comparisons).
See also Figure S2.nerve axons by 24months in wild-type mice (Valdez et al., 2010),
although this could simply reflect strain differences.
DISCUSSION
To date, WldS has been the preferred tool for assessing the
involvement of Wallerian-like axon and synapse degeneration
in rodent models of neurodegeneration (Conforti et al., 2014).
However, the relatively short-term preservation of neuromus-
cular innervation by WldS in hindlimb muscles of Nmnat2gtE/gtE
mice raises the possibility that this strategy might have
greatly underestimated the involvement of Wallerian-like mech-
anisms in some models. Likely candidates are wabbler-lethal
(Atp8a2wl/wl) and gracile axonal dystrophy (Uchl1gad/gad) mice,
in which WldS robustly protects (proximal) axons but does not
rescue neuromuscular dysfunction (Mi et al., 2005; Zhu et al.,
2012). Human SOD1G37R, SOD1G85R, and SOD1G93A transgenic
mouse models of amyotrophic lateral sclerosis (ALS) are also
candidates, althoughWldS largely fails to protect axons in these
models, suggesting that unrelated degenerative mechanisms
contribute substantially to disease signs (Vande Velde et al.,2004; Fischer et al., 2005). Because SARM1 deficiency confers
longer-lasting preservation of NMJ innervation in NMNAT2-defi-
cient mice thanWldS, it could confer a better outcome in these or
related models.
We consider that prolonged preservation of Nmnat2gtE/gtE;
Sarm1/ motor axon terminals, compared to those in
Nmnat2gtE/gtE;WldS/S mice, might reflect that local availability
of WLDS, which is required for protection (Beirowski et al.,
2009; Cohen et al., 2012), is likely to be subject to a variety
of influences, whereas protection conferred by an absence of
SARM1 will be invariant. Global expression of WLDS in homozy-
gous WldS mice does not diminish significantly with age up to
12months (Gillingwater et al., 2002), but we propose that normal
changes in physiology, from as young as 2 months of age, could
alter the stability, delivery, or activity of WLDS in Nmnat2gtE/gtE;
WldS/Smotor axon terminals, or otherwise alter the local environ-
ment, such that it can no longer effectively substitute for the lack
of NMNAT2 to promote survival. More widespread NMJ dener-
vation in gastrocnemius compared to FDB in Nmnat2gtE/gtE;
WldS/S mice suggests that changes specific to different
muscle or motor unit types are more critical to the loss ofCell Reports 21, 10–16, October 3, 2017 13
Figure 4. No Loss of Myelinated Tibial
Nerve Axons in Either Nmnat2gtE/gtE;WldS/S
or Nmnat2gtE/gtE;Sarm1/ Mice
(A) Numbers of myelinated axons in tibial nerve
(mid-calf level) from mice of the indicated geno-
types and ages (WldS/S control groups include
some Nmnat2+/gtE;WldS/S mice that were indistin-
guishable from WldS/S mice). Individual values
(n = 3–8, as shown, male and female) and means ±
SEM are plotted. No statistically significant differ-
ences were identified between groups (one-way
ANOVA with Tukey’s multiple comparisons).
(B) FluoroMyelin red-stained tibial nerve
cross-sections from 10-month-old WldS/S and
Nmnat2gtE/gtE;WldS/S mice (representative of n = 5
each genotype). No structural differences are
evident, even though Nmnat2gtE/gtE;WldS/S mice
have an advanced neuromuscular defect at this
age.WLDS-mediated protection than those relating to axon length
(FDB beingmore distal). These considerations will similarly apply
to the age-dependent loss of protection of motor axon terminals
after axotomy (and the resulting NMNAT2 loss) in homozygous
WldS mice (Gillingwater et al., 2002). Annulospiral (sensory)
nerve endings in the muscle remained protected in older mice
in that context, suggesting a motor-specific defect (Oyebode
et al., 2012). Although we have seen qualitative preservation of
annulospiral endings in Nmnat2gtE/gtE;WldS/S FDB at 10 months
(not shown), a comprehensive analysis of sensory innervation
will be required to determine whether sensory endings in general
are better preserved than motor axon terminals.
A model in which sustaining the effective potency of WLDS
locally is required for its protective effects leaves open the pos-
sibility that Sarm1 deletion may be more effective than WldS at
rescuing symptoms in models of other types of neurodegenera-
tive disease, not just those with early neuromuscular symptoms.
If the disease-causing defect in a given model additionally
reduces the activity or concentration of WLDS within axons or
synapses in some way, then its protective capacity might be
diminished. This could apply to disorders of axonal transport,
protein synthesis, or protein turnover, among others.
Our findings have therapeutic implications for human disor-
ders. Specifically, they suggest that strategies directed at
blockade of SARM1 function have the potential to bemore effec-
tive than WLDS-related therapies in neuromuscular synaptopa-
thies and potentially in a broader group of neurodegenerative
disorders. In addition, the remarkable survival and health of
Nmnat2gtE/gtE;Sarm1/ mice into old age suggests that even
long-term therapeutic interventions based on blocking SARM1
function might be both effective and well tolerated by patients.
This study confirms SARM1 as a key regulator of degeneration
caused by a NMNAT2 deficiency. Sarm1 deletion appears to
block this process indefinitely without affecting long-term sur-
vival, despite the predicted substantial reduction in nicotinamide
adenine dinucleotide (NAD)-synthesizing capacity (Gilley et al.,
2015). SARM1 has been shown to possess NADase activity
that promotes injury-induced axon or synapse degeneration
and can be inhibited by NMNAT activity (Gerdts et al., 2015;14 Cell Reports 21, 10–16, October 3, 2017Sasaki et al., 2016; Essuman et al., 2017). Therefore, a model
in which survival depends on NMNAT-dependent NAD produc-
tion balancing NAD consumption, including any resulting from
constitutive SARM1NADase activity, is attractively simple. How-
ever, NAD consumption in uninjured Sarm1/ axons has been
shown to be comparable to wild-type consumption, suggesting
that SARM1 NADase activity under normal conditions is minimal
(Sasaki et al., 2016). Instead, a situation in which a loss of
NMNAT activity results in the upregulation of SARM1 NADase
activity via intermediate signals and/or interactions to trigger
degeneration is more consistent with current findings (Sasaki
et al., 2016; Di Stefano et al., 2017).
Finally, the similarity between the progressive phenotype in
Nmnat2gtE/gtE;WldS/S mice and some mouse models of ALS is
intriguing. While there is, as yet, no established link between
NMNAT2 and ALS, the SARM1 locus has been associated
with sporadic ALS (Fogh et al., 2014), hinting at involvement
of Wallerian-like mechanisms. The neuromuscular defect in
Nmnat2gtE/gtE;WldS/S mice could thus model some aspects of
ALS disease pathogenesis. Even if the underlying mechanisms
are unrelated, Nmnat2gtE/gtE;WldS/S mice would be a useful
tool for assessing reversibility of ALS-like symptoms, because
silencing of the Nmnat2gtE gene trap allele is reversible (Gilley
et al., 2013).
EXPERIMENTAL PROCEDURES
Mouse Breeding and Maintenance
Animal work was performed in accordance with the 1986 Animals (Scientific
Procedures) Act under Project License PPL 70/7620 following an appropriate
ethical review process at the Babraham Institute. Genotyping for the
Nmnat2gtE, WldS, and Sarm1 knockout alleles was performed as described
previously (Gilley et al., 2013, 2015). Littermates were used where possible.
The ages and genders of mice used in individual experiments are described
in the figure legends.
RT-PCR
Semiquantitative endpoint RT-PCR was used to confirm Nmnat2 gene
silencing in the brains of Nmnat2gtE/gtE;WldS/S and Nmnat2gtE/gtE;Sarm1/
mice aged 10–12 months essentially as described previously (Gilley et al.,
2013).
Accelerating Rotarod Task
Locomotor performance was tested on an accelerating Rotarod (Ugo Basile,
Model 7650, Varese, Italy). Mice were familiarized with the apparatus (two
5min runs at 10 rpm) one day before testing. At each test age, mice performed
three 5 min trials (3 to 30 rpm) separated by 30 min rests. Latency to fall
(max 300 s) was recorded. Only involuntary falls were scored. Mice dismount-
ing voluntarily were placed back onto the apparatus once, but the run was
excluded from the analysis if repeated. Best trial performance was used for
statistical analyses.
H&E Staining
Transverse cryosections of gastrocnemius muscles snap frozen in liquid
nitrogen-chilled isopentane (8 mm thickness) or fixed in 4% paraformalde-
hyde (20 mm thickness) were stained with H&E as previously described
(Gilley et al., 2013). Images were captured using a MicroPublisher camera
(QImaging) on an Olympus BX50 microscope (203 objective). Staining of
snap-frozen muscle sections was optimal for visualization of muscle
structure without the artifactual muscle fiber separation seen on fixed
sections.
NMJ Innervation
Innervation of NMJs in gastrocnemius and FDB muscles was assessed
by immunofluorescent staining. Staining was performed essentially as
described previously (Krieger et al., 2013) on whole-mount muscles or lon-
gitudinal cryosections (60 mm thickness). Confocal z stack series were ac-
quired using Olympus FV1000 or Leica SPE scanning laser confocal micro-
scopes (203 or 403 objectives). Multiple z stack series were acquired for
each muscle, and z projections were generated for analysis. Endplate
occupancy was determined by assessing the extent of overlap or direct
abuttal of bIII-tubulin staining (axon terminal) with a-bungarotoxin staining
(endplate). Endplates were scored as denervated when essentially none
of the endplate (less than 5%) was deemed to be occupied by the axon
terminal, fully innervated with complete (greater than 95%) occupancy,
and partially innervated with intermediate occupancy (observer determined,
scored blind). Original z stack series were examined to exclude chance
overlay of proximal axon segments and endplates in non-adjacent focal
planes.
Isometric Muscle Tension Recordings
Force measurements for FDB muscle were made from FDB muscle-tibial
nerve preparations as described previously (Beirowski et al., 2009), except
that the proximal tendon was connected to aMLT0202 (0–25 g) isometric force
transducer (AD Instruments, Oxford, UK) and the tibial nerve was stimulated
using 0.1–0.2 ms pulses of up to 10 V using a Digitimer DS2 isolated stimulator
(Digitimer, Welwyn Garden City, UK) triggered via a Powerlab 26T interface.
Tension responses were digitized at 1 kHz using Chart 7 or Scope 4 software
(all ADInstruments).
Counts of Myelinated Tibial Nerve Axons
Transverse sections (20 mm) of fixed calf (from mid-way between knee
and ankle) were stained with FluoroMyelin red according to the manu-
facturer’s instructions (Life Technologies). Images of tibial nerves were
captured on an Olympus FV1000 point scanning confocal microscope
imaging system (403 objective). Axon counts (inferred from numbers of
myelin sheaths) were performed blind using the multi-point selection tool
in ImageJ.
Statistical Analysis
Appropriate statistical testing of data was performed using Prism
(GraphPad Software, La Jolla, USA). Tests are described in the figure legends.
A p value < 0.05 was considered significant.
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